Andrew Simon Bell

List of Publications by Year
in descending order

35	1,581	394421 19	302126 39
papers	citations	h-index	g-index

50	50	50	1922
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species. PLoS Neglected Tropical Diseases, 2021, 15, e0009490.	3.0	11
2	Novel Thienopyrimidine Inhibitors of Leishmania N-Myristoyltransferase with On-Target Activity in Intracellular Amastigotes. Journal of Medicinal Chemistry, 2020, 63, 7740-7765.	6.4	15
3	Structure-Guided Identification of Resistance Breaking Antimalarial Nâ€'Myristoyltransferase Inhibitors. Cell Chemical Biology, 2019, 26, 991-1000.e7.	5.2	26
4	Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus. Nature Chemistry, 2018, 10, 599-606.	13.6	96
5	Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase. MedChemComm, 2017, 8, 191-197.	3.4	14
6	Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files. Molecular Diversity, 2016, 20, 789-803.	3.9	6
7	High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni. PLoS Neglected Tropical Diseases, 2016, 10, e0004659.	3.0	35
8	Using a Non-Image-Based Medium-Throughput Assay for Screening Compounds Targeting N-myristoylation in Intracellular Leishmania Amastigotes. PLoS Neglected Tropical Diseases, 2014, 8, e3363.	3.0	16
9	N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis. Parasitology, 2014, 141, 37-49.	1.5	64
10	Diverse modes of binding in structures ofLeishmania majorN-myristoyltransferase with selective inhibitors. IUCrJ, 2014, 1, 250-260.	2.2	38
11	Structure-Based Design of Potent and Selective Leishmania N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 8664-8670.	6.4	56
12	<scp>TAK</scp>1 Inhibition in the <scp>DFG</scp>â€Out Conformation. Chemical Biology and Drug Design, 2013, 82, 500-505.	3.2	15
13	Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file. Molecular Diversity, 2013, 17, 319-335.	3.9	7
14	Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs. PLoS Neglected Tropical Diseases, 2012, 6, e1625.	3.0	79
15	Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy. Journal of Chemical Information and Modeling, 2012, 52, 2937-2949.	5.4	36
16	Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structureâ€"activity relationship (SAR). Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6591-6595.	2.2	6
17	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: A novel histamine H4 receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6596-6602.	2.2	32
18	Novel phosphodiesterase type 5 modulators: a patent survey (2008 â€" 2010). Expert Opinion on Therapeutic Patents, 2011, 21, 1631-1641.	5.0	22

#	Article	IF	Citations
19	The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2537-2541.	2.2	41
20	Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4088-4091.	2.2	24
21	Searching Chemical Space with the Bayesian Idea Generator. Journal of Chemical Information and Modeling, 2009, 49, 2211-2220.	5.4	11
22	Design of Second Generation Phosphodiesterase 5 Inhibitors. Current Topics in Medicinal Chemistry, 2007, 7, 405-419.	2.1	47
23	Synthesis of 1,2-disubstituted-3-alkylidenylpyrrolidines via a one-pot three-component reaction. Tetrahedron Letters, 2004, 45, 8511-8514.	1.4	14
24	Facile palladium catalysed functionalisation of 1,2-isothiazoline-3-ones and the highly diastereoselective Diels-Alder reactions of 4-vinyl-1,2-isothiazoline-3-one-1-oxides. Tetrahedron, 1999, 55, 12313-12330.	1.9	13
25	Generation and cycloadditions of 2-(N-acylamino)-1-thia-1,3-dienes part III: Control of diastereoselectivity using homochiral auxiliaries. Tetrahedron, 1998, 54, 3219-3234.	1.9	21
26	Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2031-2036.	2.2	85
27	Highly efficient diastereoselective Exo Diels-Alder reactions of homochiral 2-(N-acylamino)-1-thia-1,3-dienes: A powerful entry into optically pure thiopyrans. Tetrahedron Letters, 1996, 37, 123-126.	1.4	26
28	Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1819-1824.	2.2	565
29	Remarkably high diastereoselective exo diels-alder reactivity of 4-vinyl isothiazoline-3-one-1-oxides: The sulphoxide Syn effect.. Tetrahedron Letters, 1995, 36, 7713-7716.	1.4	8
30	Facile palladium catalysed functionalisation of 1,2-isothiazoline-3-ones. Tetrahedron Letters, 1994, 35, 6551-6554.	1.4	15
31	2(1H)-Quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives. Journal of Medicinal Chemistry, 1989, 32, 1552-1558.	6.4	17
32	7-Heteroaryl-1,2,3,5-tetrahydroimidazol[2,1-b]quinazolin-2(1H)-one derivatives with cardiac stimulant activity. Journal of Medicinal Chemistry, 1989, 32, 2042-2049.	6.4	11
33	2(1H)-Quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked,) Tj ETQq1 1 0.784314 rgBT /O	6.4	44
34	2(1H)-Quinolinones with cardiac stimulant activity. 1. Synthesis and biological activities of (six-membered heteroaryl)-substituted derivatives. Journal of Medicinal Chemistry, 1988, 31, 2048-2056.	6.4	44
35	Triazole Antifungals: Itraconazole (SporanoxÂ®), Fluconazole (DiflucanÂ®), Voriconazole (VfendÂ®), and Fosfluconazole (ProdifÂ®). , 0, , 71-82.		3